BioWorld

June 12, 2006

Pozen's Stock Crushed On Trexima Approvable Letter

The FDA's request for more safety data on Pozen Inc.'s investigational migraine drug Trexima cut the company's stock value by 60 percent Friday. (BioWorld Today) Read More

CoGenesys' $55M Financing Makes HGS Spinout Official

Merger With SIGA Would Give PharmAthene ST-246, Listing

Genentech: Cancer Competition Part Of 'Moving The Field Along'

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...